Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
Acetates
Annexin A5
Aquaporin 4
Autoantibodies
Caspase 3
Cell Death
Cell-Free Nucleic Acids
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Immunoglobulin G
Interleukin-10
Interleukin-15
Interleukin-6
Interleukin-8
Myelin-Oligodendrocyte Glycoprotein
/ toxicity
Myristates
Neuromyelitis Optica
Neutrophils
Pancreatic Elastase
Peroxidase
Phorbols
Reactive Oxygen Species
Tumor Necrosis Factor-alpha
Aquaporin-4 NMOSD
MOGAD
Myelin oligodendrocyte glycoprotein-antibody-associated disease
Neuromyelitis optica spectrum disorders
Neutrophils
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
received:
08
04
2022
accepted:
17
09
2022
entrez:
1
10
2022
pubmed:
2
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
In neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neutrophils are found in CNS lesions. We previously demonstrated that NMOSD neutrophils show functional deficiencies. Thus, we hypothesized that neutrophil accumulation in the CNS may be facilitated by impairments affecting mechanisms of neutrophil death. To evaluate cell death in blood neutrophils from aquaporin-4 (AQP4)-IgG-seropositive NMOSD and MOGAD patients as well as matched healthy controls (HC) using in vitro assays. Twenty-eight AQP4 + NMOSD and 19 MOGAD patients in stable disease phase as well as 45 age- and sex-matched HC were prospectively recruited. To induce cell death, isolated neutrophils were cultured with/without phorbol 12-myristate 13-acetate (PMA). Spontaneous and PMA-induced NETosis and apoptosis were analyzed using 7-AAD and annexin-V by flow cytometry. Caspase-3 was assessed by western blot. Myeloperoxidase-DNA complexes (MPO-DNA), MPO and elastase were evaluated by ELISA, and cell-free DNA (cfDNA) by a fluorescence-based assay. Reactive oxygen species (ROS) were evaluated by a dihydrorhodamine 123-based cytometric assay. Serum GM-CSF, IL-6, IL-8, IL-15, TNF-ɑ and IL-10 were evaluated by multiplex assays, and neurofilament light chain (NfL) by single-molecule array assay. In response to PMA, neutrophils from AQP4 + NMOSD but not from MOGAD patients showed an increased survival, and subsequent reduced cell death (29.6% annexin V AQP4 + NMOSD neutrophils showed an increased survival capacity in response to PMA when compared to matched HC neutrophils. Although the data indicate that the apoptotic but not the NETotic response is altered in these neutrophils, additional evaluations are required to validate this observation.
Sections du résumé
BACKGROUND
BACKGROUND
In neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neutrophils are found in CNS lesions. We previously demonstrated that NMOSD neutrophils show functional deficiencies. Thus, we hypothesized that neutrophil accumulation in the CNS may be facilitated by impairments affecting mechanisms of neutrophil death.
OBJECTIVE
OBJECTIVE
To evaluate cell death in blood neutrophils from aquaporin-4 (AQP4)-IgG-seropositive NMOSD and MOGAD patients as well as matched healthy controls (HC) using in vitro assays.
METHODS
METHODS
Twenty-eight AQP4 + NMOSD and 19 MOGAD patients in stable disease phase as well as 45 age- and sex-matched HC were prospectively recruited. To induce cell death, isolated neutrophils were cultured with/without phorbol 12-myristate 13-acetate (PMA). Spontaneous and PMA-induced NETosis and apoptosis were analyzed using 7-AAD and annexin-V by flow cytometry. Caspase-3 was assessed by western blot. Myeloperoxidase-DNA complexes (MPO-DNA), MPO and elastase were evaluated by ELISA, and cell-free DNA (cfDNA) by a fluorescence-based assay. Reactive oxygen species (ROS) were evaluated by a dihydrorhodamine 123-based cytometric assay. Serum GM-CSF, IL-6, IL-8, IL-15, TNF-ɑ and IL-10 were evaluated by multiplex assays, and neurofilament light chain (NfL) by single-molecule array assay.
RESULTS
RESULTS
In response to PMA, neutrophils from AQP4 + NMOSD but not from MOGAD patients showed an increased survival, and subsequent reduced cell death (29.6% annexin V
CONCLUSIONS
CONCLUSIONS
AQP4 + NMOSD neutrophils showed an increased survival capacity in response to PMA when compared to matched HC neutrophils. Although the data indicate that the apoptotic but not the NETotic response is altered in these neutrophils, additional evaluations are required to validate this observation.
Identifiants
pubmed: 36183103
doi: 10.1186/s12974-022-02600-0
pii: 10.1186/s12974-022-02600-0
pmc: PMC9526338
doi:
Substances chimiques
Acetates
0
Annexin A5
0
Aquaporin 4
0
Autoantibodies
0
Cell-Free Nucleic Acids
0
Immunoglobulin G
0
Interleukin-15
0
Interleukin-6
0
Interleukin-8
0
Myelin-Oligodendrocyte Glycoprotein
0
Myristates
0
Phorbols
0
Reactive Oxygen Species
0
Tumor Necrosis Factor-alpha
0
Interleukin-10
130068-27-8
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Peroxidase
EC 1.11.1.7
Pancreatic Elastase
EC 3.4.21.36
Caspase 3
EC 3.4.22.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239Informations de copyright
© 2022. The Author(s).
Références
J Evol Biochem Physiol. 2021;57(3):429-450
pubmed: 34226754
Elife. 2017 Jun 02;6:
pubmed: 28574339
Front Immunol. 2019 Mar 19;10:502
pubmed: 30941136
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Immunol. 2013 Sep 1;191(5):2647-56
pubmed: 23904163
Br J Cancer. 2017 Jul 25;117(3):385-397
pubmed: 28632731
Mult Scler. 2012 Dec;18(12):1801-3
pubmed: 22495946
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
Ann Neurol. 2022 Apr;91(4):532-547
pubmed: 35167145
J Immunol. 2018 Jan 15;200(2):869-879
pubmed: 29196457
Mult Scler. 2016 Feb;22(2):160-73
pubmed: 26540731
Neurology. 2019 Sep 24;93(13):e1299-e1311
pubmed: 31471502
FASEB J. 2006 Jul;20(9):1504-6
pubmed: 16720733
J Immunol. 2009 Nov 15;183(10):6198-206
pubmed: 19841168
Ann Neurol. 2012 Mar;71(3):323-33
pubmed: 22374891
Acta Neuropathol Commun. 2013 May 08;1:5
pubmed: 24252536
Blood. 1997 Nov 1;90(9):3356-63
pubmed: 9345017
J Neuroinflammation. 2020 Sep 3;17(1):261
pubmed: 32883348
J Neuroinflammation. 2016 Nov 1;13(1):281
pubmed: 27802825
Front Neurol. 2018 Oct 23;9:888
pubmed: 30405519
Curr Protoc Immunol. 2001 May;Chapter 7:Unit 7.23
pubmed: 18432834
Brain. 2010 Feb;133(Pt 2):349-61
pubmed: 20047900
Cell Res. 2011 Feb;21(2):290-304
pubmed: 21060338
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33645550
Thorax. 2018 Feb;73(2):134-144
pubmed: 28916704
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 4;7(5):
pubmed: 32753407
Nat Rev Dis Primers. 2020 Oct 22;6(1):85
pubmed: 33093467
Brain. 2002 Jul;125(Pt 7):1450-61
pubmed: 12076996
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Front Neurol. 2022 Jun 10;13:875456
pubmed: 35756930
J Neuroinflammation. 2021 May 1;18(1):105
pubmed: 33933106
Int Immunol. 2010 Oct;22(10):827-38
pubmed: 20739460
Brain. 2007 May;130(Pt 5):1194-205
pubmed: 17282996
Front Immunol. 2021 Mar 04;12:649693
pubmed: 33746988
J Cell Biol. 2012 Sep 3;198(5):773-83
pubmed: 22945932
Front Immunol. 2021 Feb 23;12:628024
pubmed: 33717149
J Leukoc Biol. 2000 Jul;68(1):15-20
pubmed: 10914485
J Neuroinflammation. 2016 Nov 1;13(1):282
pubmed: 27802824
Cell Death Discov. 2018 Apr 27;4:51
pubmed: 29736268
Shock. 2000 May;13(5):361-6
pubmed: 10807010
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):927-936
pubmed: 29875186
Brain Pathol. 2013 Nov;23(6):661-83
pubmed: 24118483
Biochem J. 1997 Jul 1;325 ( Pt 1):147-53
pubmed: 9224640
Ann Neurol. 2011 Dec;70(6):943-54
pubmed: 22069219
Blood. 2014 Jan 23;123(4):597-600
pubmed: 24458280
Nat Chem Biol. 2011 Feb;7(2):75-7
pubmed: 21170021
Mult Scler. 2012 Apr;18(4):398-408
pubmed: 22343184
J Neuroinflammation. 2012 Jan 19;9:14
pubmed: 22260418
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
J Cell Biol. 2007 Jan 15;176(2):231-41
pubmed: 17210947
J Neurol Sci. 2011 Jul 15;306(1-2):82-90
pubmed: 21550068
Front Immunol. 2021 Jan 05;11:584116
pubmed: 33469455
Lancet Neurol. 2021 Sep;20(9):762-772
pubmed: 34418402
Nat Med. 2009 Jun;15(6):623-5
pubmed: 19448636
PLoS One. 2012;7(3):e32439
pubmed: 22403660
J Neurol Sci. 2010 Apr 15;291(1-2):52-6
pubmed: 20117794
Neuroimmunomodulation. 2018;25(4):215-224
pubmed: 30544111
Leukemia. 1997 Apr;11(4):466-78
pubmed: 9096685
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
Mult Scler Relat Disord. 2020 Oct;45:102345
pubmed: 32653734
Acta Neuropathol. 2013 Jun;125(6):815-27
pubmed: 23579868
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 24;9(3):
pubmed: 35210295
Front Immunol. 2018 Jul 23;9:1694
pubmed: 30083159